Xtant Medical raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company’s prior guidance of $73 million to $75 million. The revised guidance range represents annual revenue growth of approximately 29% to 33% compared to full year 2022 revenue, and excludes any potential contributions from the Surgalign transaction, if and when that transaction closes.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XTNT:
- Xtant Medical Announces Second Quarter Revenue Growth of 32%
- XTNT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Xtant Medical Wins Auction for Surgalign’s Hardware and Biologics Business
- Xtant is winning bidder for Surgalign’s hardware and biologics business
- Xtant Medical to Issue Second Quarter 2023 Financial Results on August 1, 2023